# HRS-4642 in Combination With AG for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer

Source: https://onco.cc/trials/nct06587061/  
OnCo record `nct06587061` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in pancreatic cancer, run by Ruijin Hospital, now recruiting.

## Summary

HRS-4642 in Combination With AG for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer is a phase 2, interventional study registered as NCT06587061 by Ruijin Hospital, with a registry enrolment figure of 30 participants, started 2024-12-03 and due to reach its primary completion in 2027-06. Interventions recorded: HRS-4642+AG. Conditions listed: Pancreatic Cancer. Primary outcome: Adverse events (AEs); Objective Response Rate (ORR). Pancreatic eligibility wording from the registry: "Pathologically or cytologically confirmed ductal adenocarcinoma of the pancreas; and subjects must have at least one measurable lesion as defined by RECIST v1". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT06587061
- Phase: 2
- Setting: An Exploratory Clinical Study of HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer
- Sponsor: Ruijin Hospital
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT06587061: https://clinicaltrials.gov/study/NCT06587061

## Connected records

- cancers: [Resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/resectable-pdac/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06587061.json